Trial Profile

Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabigatran etexilate (Primary) ; Acenocoumarol
Indications Embolism; Ischaemic stroke; Stroke
Focus Adverse reactions; Therapeutic Use
Acronyms SEDMAN

Most Recent Events

25 Feb 2022 Data was used from GRECOS (Genotyping Recurrence Risk of Stroke) and SEDMAN (Dabigatran Study in the Early Phase of Stroke, New Neuroimaging Markers and Biomarkers) studies to assess biological age acceleration in Women with ischemic stroke compared to men published in the Stroke
19 Mar 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2019.
19 Mar 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com